Alembic Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Key Takeaways

• India branded business lags, again: Domestic revenue grew just 6% YoY, underperforming the market for the third or fourth straight year. Management now targets a return to market-level growth by Q1 FY27, a promise it has made and missed before.
• U.S. generics: volume up, price down: The U.S. business grew 6% YoY on higher volumes and new launches, but persistent pricing pressure and rising competitive intensity are shrinking the opportunity set.
• Pivya is the strategic bet, with a near-term cost: The first branded U.S. product launches in February 2026. Management expects a 12- to 18-month prescription ramp but warns of a margin drag from MR costs and royalties until scale is reached.
• Core margins are improving, and that matters: EBITDA margin rose to 25% from 23% a year ago on operating leverage and spending discipline. Better facility utilization over the next few quarters is expected to drive further expansion, which management frames as a cushion for Pivya investment.
• What to watch next quarter: Whether the India business actually accelerates toward market growth in Q1 FY27, the initial prescription uptake of Pivya post-launch, and the magnitude of the margin impact from that launch.

India Branded Business: The Persistent Underperformer

• Growth gap: The domestic business has lagged market growth for 3 to 4 years. Management attributes this to being too conservative on doctor spend relative to peers, particularly under the Uniform Code of Pharmaceutical Marketing Practices (UCMP), and a post-COVID normalization that hit large brands.
• Q3 performance: India branded revenue grew 6% YoY. Gynaecology, ophthalmology and animal healthcare showed accelerating momentum, while anti-infectives grew in line with the portfolio average.
• The Q1 FY27 promise: Management expects the business to return to market-level growth by Q1 of the coming financial year, driven by operational execution rather than new launches. When pressed on why prior commitments were not met, management did not address the track record.
• Field force posture: No further large expansions are planned at this point, though management left the door open if operational performance meets expectations.

Shaunak Amin: "I personally don't think at this point we are looking at any further large expansions. But that being said, yes, there is a large opportunity in the India market, assuming if things start going as per our expectations operationally, I mean, we would consider and look at those plans to take it forward."

U.S. Business: Volume Growth Meets Price Headwinds

• Current trajectory: U.S. revenue grew 6% YoY, supported by higher volumes and launches over recent quarters, despite continuing pricing pressure. The Q3 base last year was elevated by a few large launches, making the comparison tougher.
• Competitive intensity rising: Management noted that due to increased competition, the number of attractive opportunities is shrinking, even as volumes continue to grow.
• Mid-teens ambition: Management expects U.S. business to grow at a mid-teens constant-currency rate going into FY27 and FY28, ideally 10% to 15% annually. Injectable and complex products are expected to drive this over the next couple of years as additional approvals come through.
• Near-term launches: The company hopes to launch another 4 to 5 products in Q4 FY26.
• Pipeline depth: Cumulative ANDA filings stand at 270, with 23 ANDA approvals and 20 tentative approvals in hand.

Pivya: The Branded Pivot

• The product: Pivya is a first-line oral antibiotic for uncomplicated UTIs in women, and Alembic's first branded product in the U.S. market. Launch is on track for February 2026 (Q4 FY26), with medical representatives being onboarded and material already shipping to the U.S.
• The strategic logic: Management frames Pivya as the start of a strategic shift toward a part-branded business that can be ramped up over the coming years, reducing reliance on pure generics.
• The margin math: Until the product scales, there will be no margin contribution: MR costs, royalty payments and other launch expenses will be a drag. Management declined to quantify the opex budget for FY27, asking analysts to wait a couple of quarters for clarity and suggesting that margin expansion from the core business could serve as a cushion.
• Ramp timeline: Prescription share is expected to scale over the next 12 to 18 months, with management confident in the medium- to long-term market opportunity.

Pranav Amin: "Till the product starts scaling up we wouldn't have any margin because until it gets to a certain point, you have your MR cost, you have the royalty payments, you have everything else. So let's wait for a couple of quarters, and you guys will all get a much better idea."

Margins: Core Strength, Pivya Overhang

• Q3 margin walk: Gross margin moderated to 72% from 74% a year ago on product mix changes and pricing challenges, partially offset by cost improvement programs in the international business. EBITDA margin improved to 25% from 23%, reflecting operating leverage and prudent discretionary spending management.
• 9-month trend: EBITDA before R&D grew 25% YoY, supported by strong revenue growth and better capacity utilization across facilities.
• Labour Code provision: A one-time INR 42 crores provision for employee benefits under the New Labour Code was booked; management clarified it does not impact operating performance or immediate cash flow.
• Forward view: Core business margins have shown improvement this financial year. With better capacity utilization in existing facilities, further margin expansion is expected over the next few quarters. Management suggests this expansion could cushion Pivya-related expenses, though the net impact remains unquantified.

R&D and Pipeline

• FY26 spend: Full-year R&D guidance is INR 600 crores to INR 650 crores. For FY27, management indicated spend will likely stay in the same 8% to 9% of revenue range, with formal guidance to come at Q4 results.
• Focus areas: Investment is concentrated on complex and differentiated products: injectables, peptides, oral solids and drug discovery, with emphasis on early-entry opportunities including First to File, Day 1 and NCE-1 launches.
• New facility ramp: Strategic contracts alongside in-house products are expected to help scale utilization in new facilities over the next 12 to 18 months.
• Quarterly activity: One ANDA was filed during the quarter, 7 U.S. approvals were received, and 2 approved products were launched. Four new products were launched in India.

International and ROW Markets

• ROW momentum: Rest-of-world markets grew 36% YoY, reflecting strategic geographic expansion and focused execution.
• Out-licensing deals: The company executed several out-licensing and manufacturing agreements during the quarter, supporting its injectable and oncology capabilities.

Guidance & Commitments

Key Metrics